$MDGL
MADRIGAL PHARMACEUTICALS, INC. Stock $mdgl

$mdgl Overview Financials Valuation SEC Filings Company Website

2013 Q3 Form 10-Q Financial Statement

#000110465913058569 Filed on August 01, 2013

Income Statement

Concept	2013 Q3	2013 Q2	2012 Q2
Revenue	$0.00	$0.00	$0.00
YoY Change			-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.200M	$4.200M	$2.900M
YoY Change	50.0%	44.83%	0.0%
% of Gross Profit
Research & Development	$17.62M	$17.88M	$11.25M
YoY Change	50.07%	58.87%	8.02%
% of Gross Profit
Depreciation & Amortization	$100.0K	$100.0K	$300.0K
YoY Change	-50.0%	-66.67%	-25.0%
% of Gross Profit
Operating Expenses	$21.79M	$22.06M	$14.13M
YoY Change	49.9%	56.1%	5.77%
Operating Profit	-$21.79M	-$22.06M	-$14.13M
YoY Change	49.9%	56.1%	17.7%
Interest Expense	-$721.0K	-$724.0K	-$486.0K
YoY Change	57.77%	48.97%	-1.42%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$22.50M	-$22.80M	-$14.60M
YoY Change	50.0%	56.16%	16.8%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$22.50M	-$22.80M	-$14.60M
YoY Change	50.0%	56.16%	16.8%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$11.25M	-$11.40M	-$9.125M
COMMON SHARES
Basic Shares Outstanding	69.06M shares	69.13M shares	57.64M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2013 Q3	2013 Q2	2012 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$53.40M	$70.20M	$44.70M
YoY Change	-3.09%	57.05%	-28.93%
Cash & Equivalents	$25.48M	$33.78M	$25.59M
Short-Term Investments	$27.90M	$36.40M	$19.10M
Other Short-Term Assets	$1.400M	$1.600M	$800.0K
YoY Change	75.0%	100.0%	0.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$54.74M	$71.84M	$45.50M
YoY Change	-2.07%	57.89%	-28.57%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.488M	$1.620M	$1.166M
YoY Change	23.49%	38.94%	-16.71%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$433.0K	$464.0K	$500.0K
YoY Change	-7.08%	-7.2%	0.0%
Total Long-Term Assets	$1.921M	$2.084M	$1.700M
YoY Change	12.14%	22.59%	-10.53%
TOTAL ASSETS
Total Short-Term Assets	$54.74M	$71.84M	$45.50M
Total Long-Term Assets	$1.921M	$2.084M	$1.700M
Total Assets	$56.66M	$73.92M	$47.20M
YoY Change	-1.65%	56.62%	-28.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.693M	$5.222M	$3.500M
YoY Change	54.28%	49.2%	75.0%
Accrued Expenses	$12.80M	$9.500M	$6.900M
YoY Change	72.97%	37.68%	18.97%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$7.400M	$5.300M	$7.900M
YoY Change	-6.33%	-32.91%	154.84%
Total Short-Term Liabilities	$25.93M	$20.07M	$18.25M
YoY Change	36.73%	9.95%	19.31%
LONG-TERM LIABILITIES
Long-Term Debt	$16.10M	$18.40M	$8.400M
YoY Change	147.69%	119.05%	-39.13%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$16.12M	$18.42M	$8.400M
YoY Change	149.61%	119.25%	-39.13%
TOTAL LIABILITIES
Total Short-Term Liabilities	$25.93M	$20.07M	$18.25M
Total Long-Term Liabilities	$16.12M	$18.42M	$8.400M
Total Liabilities	$42.05M	$38.49M	$26.70M
YoY Change	65.41%	44.15%	-8.56%
SHAREHOLDERS EQUITY
Retained Earnings	-$527.3M	-$504.7M
YoY Change	18.99%
Common Stock	$541.9M	$540.2M
YoY Change	14.01%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$14.61M	$35.44M	$20.46M
YoY Change
Total Liabilities & Shareholders Equity	$56.66M	$73.92M	$47.16M
YoY Change	-1.65%	56.74%	-28.1%

Cashflow Statement

Concept	2013 Q3	2013 Q2	2012 Q2
OPERATING ACTIVITIES
Net Income	-$22.50M	-$22.80M	-$14.60M
YoY Change	50.0%	56.16%	16.8%
Depreciation, Depletion And Amortization	$100.0K	$100.0K	$300.0K
YoY Change	-50.0%	-66.67%	-25.0%
Cash From Operating Activities	-$16.59M	-$19.92M	-$13.10M
YoY Change	25.11%	52.06%	7.82%
INVESTING ACTIVITIES
Capital Expenditures	-$20.00K	-$390.0K	-$60.00K
YoY Change	-90.48%	550.0%	50.0%
Acquisitions
YoY Change
Other Investing Activities	$8.510M	$19.01M	$3.760M
YoY Change	-228.36%	405.59%	-126.61%
Cash From Investing Activities	$8.500M	$18.62M	$3.700M
YoY Change	-224.27%	403.24%	-126.11%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-210.0K	120.0K	440.0K
YoY Change	-100.88%	-72.73%	-98.74%
NET CHANGE
Cash From Operating Activities	-16.59M	-19.92M	-13.10M
Cash From Investing Activities	8.500M	18.62M	3.700M
Cash From Financing Activities	-210.0K	120.0K	440.0K
Net Change In Cash	-8.300M	-1.180M	-8.960M
YoY Change	-315.58%	-86.83%	-205.16%
FREE CASH FLOW
Cash From Operating Activities	-$16.59M	-$19.92M	-$13.10M
Capital Expenditures	-$20.00K	-$390.0K	-$60.00K
Free Cash Flow	-$16.57M	-$19.53M	-$13.04M
YoY Change	26.97%	49.77%	7.68%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2013Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	540155000	USD
CY2013Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	9000	USD
CY2013Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-504735000	USD
	dei	Entity Registrant Name EntityRegistrantName	SYNTA PHARMACEUTICALS CORP
	dei	Entity Central Index Key EntityCentralIndexKey	0001157601
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2013-06-30
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	225000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	453000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	21270000	USD
CY2013Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	21941000	USD
CY2013Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	20321000	USD
CY2013Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1699000	USD
CY2013Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1144000	USD
CY2013Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	781000	USD
CY2012Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3272000	USD
CY2012Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	999000	USD
CY2012Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	856000	USD
CY2013Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2013Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2013Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2013Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	68930082	shares
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5661000	USD
CY2012Q4	snta	Accrued Contract Research Costs AccruedContractResearchCosts	4761000	USD
CY2012Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	13000	USD
CY2012Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	7924000	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	23486000	USD
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
CY2013Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	69059083	shares
	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">(1) Nature of Business</font></b></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Synta Pharmaceuticals Corp. (the Company) was incorporated in March 2000 and commenced operations in July 2001. The Company is a biopharmaceutical company focusing on discovering, developing and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases.</font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The Company is subject to risks common to emerging companies in the drug development and pharmaceutical industry including, but not limited to, uncertainty of product development and commercialization, lack of marketing and sales history, dependence on key personnel, uncertainty of market acceptance of products, product liability, uncertain protection of proprietary technology, potential inability to raise additional financing and compliance with the U.S. Food and Drug Administration and other government regulations.</font></p> </div>
CY2012Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	11252000	USD
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	1000	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Use of Estimates</font></b></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Significant items subject to such estimates and assumptions include contract research accruals, recoverability of long-lived assets, measurement of stock-based compensation, and the periods of performance under collaborative research and development agreements. The Company bases its estimates on historical experience and various other assumptions that management believes to be reasonable under the circumstances. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.</font></p> </div>
CY2013Q2	us-gaap	Revenue From Grants RevenueFromGrants	0	USD
	us-gaap	Revenue From Grants RevenueFromGrants	0	USD
	us-gaap	Revenue From Grants RevenueFromGrants	147000	USD
CY2011Q1	snta	Amount Of Grant Awarded AmountOfGrantAwarded	1000000	USD
CY2012Q2	us-gaap	Revenue From Grants RevenueFromGrants	0	USD
CY2012Q2	us-gaap	Operating Expenses OperatingExpenses	14134000	USD
CY2012Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-486000	USD
	snta	Increase Decrease Accrued Contract And Research Costs IncreaseDecreaseAccruedContractAndResearchCosts	1150000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	22757000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	43959000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-28699000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-1194000	USD
CY2013Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-22787000	USD
CY2012Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	20096000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1174000	USD
CY2013Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1620000	USD
CY2013Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	100000	USD
CY2012Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	300000	USD
CY2013Q2	snta	Accrued Liabilities Current Excluding Accrued Contract Research Costs AccruedLiabilitiesCurrentExcludingAccruedContractResearchCosts	3624000	USD
CY2012Q4	snta	Accrued Liabilities Current Excluding Accrued Contract Research Costs AccruedLiabilitiesCurrentExcludingAccruedContractResearchCosts	5127000	USD
CY2013Q2	us-gaap	Availableforsale Securities Gross Unrealized Gain AvailableforsaleSecuritiesGrossUnrealizedGain	12000	USD
CY2013Q2	us-gaap	Available For Sale Securities Gross Unrealized Losses1 AvailableForSaleSecuritiesGrossUnrealizedLosses1	3000	USD
CY2012Q4	snta	Cash And Cash Equivalents And Available For Sale Securities Gross Unrealized Gains CashAndCashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGains	3000	USD
CY2013Q2	snta	Cash And Cash Equivalents And Available For Sale Securities Gross Unrealized Gains CashAndCashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGains	12000	USD
CY2012Q4	snta	Cash And Cash Equivalents And Available For Sale Securities Gross Unrealized Losses CashAndCashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLosses	1000	USD
CY2013Q2	snta	Cash And Cash Equivalents And Available For Sale Securities Gross Unrealized Losses CashAndCashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLosses	3000	USD
CY2013Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1591000	USD
CY2012Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	731000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1558000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2807000	USD
CY2013Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	15444000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y29D
CY2013Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	452000	USD
CY2013Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	9460000	USD
CY2013Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	9215000	USD
CY2013Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	4596000	USD
CY2013Q2	us-gaap	Secured Debt SecuredDebt	23723000	USD
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	33783000	USD
CY2013Q2	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	36420000	USD
CY2013Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1637000	USD
CY2013Q2	us-gaap	Assets Current AssetsCurrent	71840000	USD
CY2013Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	464000	USD
CY2013Q2	us-gaap	Assets Assets	73924000	USD
CY2013Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	5222000	USD
CY2013Q2	snta	Accrued Contract Research Costs AccruedContractResearchCosts	5911000	USD
CY2013Q2	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	8000	USD
CY2013Q2	us-gaap	Secured Debt Current SecuredDebtCurrent	5306000	USD
CY2013Q2	us-gaap	Liabilities Current LiabilitiesCurrent	20071000	USD
CY2013Q2	us-gaap	Secured Long Term Debt SecuredLongTermDebt	18417000	USD
CY2013Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	18417000	USD
CY2013Q2	us-gaap	Liabilities Liabilities	38488000	USD
CY2013Q2	us-gaap	Common Stock Value CommonStockValue	7000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	28802000	USD
	snta	Proceeds From Issuance Of Common Stock To Related Parties ProceedsFromIssuanceOfCommonStockToRelatedParties	5000000	USD
	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	13500000	USD
	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	2165000	USD
CY2013Q2	us-gaap	Stockholders Equity StockholdersEquity	35436000	USD
CY2013Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	73924000	USD
CY2013Q2	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	81512000	USD
CY2012Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	19087000	USD
CY2012Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	786000	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	101385000	USD
CY2012Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	458000	USD
CY2012Q4	us-gaap	Assets Assets	103017000	USD
CY2012Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	1000	USD
CY2012Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	4464000	USD
CY2012Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	4465000	USD
CY2012Q4	us-gaap	Liabilities Liabilities	27951000	USD
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	7000	USD
CY2012Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	536277000	USD
CY2012Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	2000	USD
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-461220000	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	75066000	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	103017000	USD
CY2012Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2012Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2012Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2012Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	68930082	shares
CY2013Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	69059083	shares
CY2013Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	69059083	shares
	snta	Total Revenues TotalRevenues	147000	USD
CY2013Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	17876000	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	34256000	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	23318000	USD
CY2013Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4187000	USD
CY2012Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2882000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8065000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5528000	USD
CY2013Q2	us-gaap	Operating Expenses OperatingExpenses	22063000	USD
	us-gaap	Operating Expenses OperatingExpenses	42321000	USD
	us-gaap	Operating Expenses OperatingExpenses	28846000	USD
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-22063000	USD
CY2012Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-14134000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-42321000	USD
CY2013Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-724000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-972000	USD
CY2012Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-14620000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-43515000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-29671000	USD
CY2013Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.33
CY2012Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.25
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.63
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.52
CY2013Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	69034823	shares
CY2012Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	57650412	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	69013217	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	57008702	shares
CY2013Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	2000	USD
CY2012Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-15000	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	7000	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	1000	USD
CY2013Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-22785000	USD
CY2012Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14635000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-43508000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-29670000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2807000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1558000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	851000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	278000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	6000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-128000	USD
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-440000	USD
	snta	Increase Decrease Accrued Contract And Research Costs IncreaseDecreaseAccruedContractAndResearchCosts	935000	USD
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-1503000	USD
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-1475000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-42133000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-28349000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	61284000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	13345000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	671000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	212000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-17996000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-9624000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1071000	USD
	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	306000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	6000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	5000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	12400000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	33491000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-47729000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-4482000	USD
	us-gaap	Interest Paid InterestPaid	1322000	USD
	us-gaap	Interest Paid InterestPaid	907000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30075000	USD
CY2012Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25593000	USD

Files In Submission

Name	View Source	Status
0001104659-13-058569-index-headers.html	Edgar Link	pending
0001104659-13-058569-index.html	Edgar Link	pending
0001104659-13-058569.txt	Edgar Link	pending
0001104659-13-058569-xbrl.zip	Edgar Link	pending
a13-13847_110q.htm	Edgar Link	pending
a13-13847_1ex31d1.htm	Edgar Link	pending
a13-13847_1ex31d2.htm	Edgar Link	pending
a13-13847_1ex32d1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
R1.htm	Edgar Link	pending
R1.xml	Edgar Link	unprocessable
R10.htm	Edgar Link	pending
R10.xml	Edgar Link	unprocessable
R11.htm	Edgar Link	pending
R11.xml	Edgar Link	unprocessable
R12.htm	Edgar Link	pending
R12.xml	Edgar Link	unprocessable
R13.htm	Edgar Link	pending
R13.xml	Edgar Link	unprocessable
R14.htm	Edgar Link	pending
R14.xml	Edgar Link	unprocessable
R15.htm	Edgar Link	pending
R15.xml	Edgar Link	unprocessable
R16.htm	Edgar Link	pending
R16.xml	Edgar Link	unprocessable
R17.htm	Edgar Link	pending
R17.xml	Edgar Link	unprocessable
R18.htm	Edgar Link	pending
R18.xml	Edgar Link	unprocessable
R19.htm	Edgar Link	pending
R19.xml	Edgar Link	unprocessable
R2.htm	Edgar Link	pending
R2.xml	Edgar Link	unprocessable
R20.htm	Edgar Link	pending
R20.xml	Edgar Link	unprocessable
R21.htm	Edgar Link	pending
R21.xml	Edgar Link	unprocessable
R22.htm	Edgar Link	pending
R22.xml	Edgar Link	unprocessable
R23.htm	Edgar Link	pending
R23.xml	Edgar Link	unprocessable
R24.htm	Edgar Link	pending
R24.xml	Edgar Link	unprocessable
R25.htm	Edgar Link	pending
R25.xml	Edgar Link	unprocessable
R26.htm	Edgar Link	pending
R26.xml	Edgar Link	unprocessable
R27.htm	Edgar Link	pending
R27.xml	Edgar Link	unprocessable
R28.htm	Edgar Link	pending
R28.xml	Edgar Link	unprocessable
R29.htm	Edgar Link	pending
R29.xml	Edgar Link	unprocessable
R3.htm	Edgar Link	pending
R3.xml	Edgar Link	unprocessable
R30.htm	Edgar Link	pending
R30.xml	Edgar Link	unprocessable
R31.htm	Edgar Link	pending
R31.xml	Edgar Link	unprocessable
R32.htm	Edgar Link	pending
R32.xml	Edgar Link	unprocessable
R4.htm	Edgar Link	pending
R4.xml	Edgar Link	unprocessable
R5.htm	Edgar Link	pending
R5.xml	Edgar Link	unprocessable
R6.htm	Edgar Link	pending
R6.xml	Edgar Link	unprocessable
R7.htm	Edgar Link	pending
R7.xml	Edgar Link	unprocessable
R8.htm	Edgar Link	pending
R8.xml	Edgar Link	unprocessable
R9.htm	Edgar Link	pending
R9.xml	Edgar Link	unprocessable
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
snta-20130630.xml	Edgar Link	completed
snta-20130630.xsd	Edgar Link	pending
snta-20130630_cal.xml	Edgar Link	unprocessable
snta-20130630_def.xml	Edgar Link	unprocessable
snta-20130630_lab.xml	Edgar Link	unprocessable
snta-20130630_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MDGL
MADRIGAL PHARMACEUTICALS, INC. Stock $mdgl

2013 Q3 Form 10-Q Financial Statement

#000110465913058569 Filed on August 01, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MDGL MADRIGAL PHARMACEUTICALS, INC. Stock $mdgl

2013 Q3 Form 10-Q Financial Statement

#000110465913058569 Filed on August 01, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MDGL
MADRIGAL PHARMACEUTICALS, INC. Stock $mdgl